Canada · Delayed Price · Currency is CAD Spectral Medical Earnings Call Transcripts
Fiscal Year 2025
-
Full TIGRIS trial enrollment and strong results have advanced regulatory progress, with PMA submission now targeted for early Q1 2026 following additional FDA feedback. Commercialization plans with Vantive are well underway, and financial resources are sufficient to support operations through late next year.
-
Tigris phase III trial demonstrated significant mortality reduction at 90 days for endotoxic septic shock, with strong efficacy and safety results supporting an FDA submission planned for October. Commercialization efforts with Baxter are progressing, and further data and regulatory milestones are expected in the coming year.
-
The meeting highlighted strong clinical and operational progress, including full TIGRIS study enrollment and robust financial support from partners. Strategic focus is on regulatory submission, commercialization with Vantive, and unlocking significant shareholder value, with key catalysts expected in the coming year.
-
Full enrollment of the Tigris trial and a $10M Vantive financing mark major milestones, with top-line results expected by mid-August and FDA submission in October. The addressable market is estimated at 120,000–130,000 patients annually, and adoption is expected to be strong due to clinical and economic benefits.
Fiscal Year 2024
-
Tigris trial enrollment slowed due to a saline shortage but is expected to reach full enrollment by end of Q1 2025, with top-line data in early Q3 and FDA submission by Q3 2025. Financial runway is sufficient for enrollment, with additional funding planned for regulatory phases.
-
The meeting highlighted strong progress in the Tigris trial, robust financial positioning, and a long-term commercialization partnership with Baxter. Shareholders received updates on board changes, strategic initiatives, and key challenges, with management addressing questions on adoption, trial execution, and future funding.